

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claims 1-52 (canceled)

Claim 53 (previously presented): An anticodon oligomer complementary to bcl-2 mRNA consisting of from 18-35 bases and comprising the nucleotide sequence TCTCCCAGCGTGCGCCAT (SEQ ID NO:17).

Claims 54-69 (canceled)

Claim 70 (currently amended): An anticodon oligomer, wherein said anticodon oligomer is from 10 to 40 bases in length and is complementary to a portion of a human bcl-2 mRNA ~~or a portion of a human bcl-2 primary transcript~~.

Claim 71 (canceled)

Claim 72 (currently amended): The anticodon oligomer of Claim 70, wherein said anticodon oligomer is an antisense oligonucleotide complementary to a splice acceptor site of a human bcl-2 mRNA ~~primary transcript~~.

Claim 73 (currently amended): The anticodon oligomer of Claim 70, wherein said anticodon oligomer is an antisense oligonucleotide complementary to a splice donor site of a human bcl-2 mRNA ~~primary transcript~~.

Claim 74 (currently amended): The anticodon oligomer of Claim 70, wherein said anticodon oligomer is 10 to 40 bases in length and is complementary to a 5'-untranslated region of a human bcl-2 mRNA ~~or a human bcl-2 primary transcript~~.

Claim 75 (previously presented): A composition comprising the anticodon oligomer of Claims 53, 70, 72, 73 or 74; and a pharmaceutically acceptable carrier.

Claim 76 (previously presented): The anticodon oligomer of Claim 53, wherein said anticodon oligomer contains at least one phosphorothioate-modified nucleotide.

Claim 77 (previously presented): A composition comprising the anticodon oligomer of Claim 76; and a pharmaceutically acceptable carrier.

Claim 78 (previously presented): The anticodon oligomer of Claim 76, wherein said anticodon oligomer is a phosphodiester/phosphorothioate chimera.

Claim 79 (previously presented): The anticodon oligomer of Claim 76 wherein the oligonucleotide comprises at least 2 to 3 phosphorothioate linkages.

Claim 80 (previously presented): A composition comprising the anticodon oligomer of Claim 78 or 79; and a pharmaceutically acceptable carrier.

Claim 81 (previously presented): The anticodon oligomer of Claim 53, wherein said anticodon oligomer contains at least one phosphoramidate-modified nucleotide.

Claim 82 (previously presented): The anticodon oligomer of Claims 70, 72, 73 or 74, wherein said anticodon oligomer contains at least one phosphorothioate-modified nucleotide.

Claim 83 (previously presented): A composition comprising the anticodon oligomer of Claim 82; and a pharmaceutically acceptable carrier.

Claim 84 (previously presented): The anticodon oligomer of Claim 82, wherein said anticodon oligomer is a phosphodiester/phosphorothioate chimera.

Claim 85 (previously presented): The anticodon oligomer of Claim 84 wherein the oligonucleotide comprises at least 2 to 3 phosphorothioate linkages.

Claim 86 (previously presented): A composition comprising the anticodon oligomer of Claim 84 and a pharmaceutically acceptable carrier.

Claim 87 (previously presented): A composition comprising the anticode oligomer of Claim 85 and a pharmaceutically acceptable carrier.

Claim 88 (previously presented): The anticode oligomer of Claim 70, 72, 73 or 74, wherein said anticode oligomer contains at least one phosphoramidate-modified nucleotide.